Colorectal News and Research

RSS

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the fourth quarter and fiscal year ended December 31, 2009.

5 Apr 2010

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

NewYork-Presbyterian Hospital installs high-tech imaging systems for heart and vascular surgeries

In a move that could change the way many patients undergo surgery, NewYork-Presbyterian Hospital has installed five state-of-the-art Siemens Artis zeego- medical imaging systems that provide faster, more accurate 3-D images of the body with a quality never before attainable.

3 Apr 2010

2010 DDW conference to highlight breakthrough research on GI health

Thousands of physicians, researchers and academics from around the world will gather in New Orleans in early May for Digestive Disease Week- (DDW-), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

2 Apr 2010

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.

2 Apr 2010

Advocates urge Representatives to support Colorectal Cancer Prevention, Early Detection and Treatment Act

On March 30-31, 2010, advocates from all 50 states, the District of Columbia and Puerto Rico called their Representatives in Congress, urging them to support the Colorectal Cancer Prevention, Early Detection and Treatment Act (H.R. 1189) during the annual Congressional Butt-In.

1 Apr 2010

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.

30 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

People with diabetes who undergo cancer surgery have greater risk of death: Study

People with diabetes who undergo cancer surgery are more likely to die in the month following their operations than those who have cancer but not diabetes, an analysis by Johns Hopkins researchers suggests.

29 Mar 2010

Genome sequencing of tumors biopsied from women with invasive breast cancer

Tumors biopsied from women with invasive breast cancer are having their genomes sequenced in an attempt to develop a DNA profile that one day may identify ahead of time the patients who will most likely respond to chemotherapy with an aromatase inhibitor. Aromatase inhibitors are a class of chemotherapeutic agents that block the production of estrogen in postmenopausal women.

27 Mar 2010

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

The Growing Financial Burden Of Health Care: National And State Trends, 2001-2006 - This paper examines the ratio of total out-of-pocket spending for health care and insurance to total family income, using data from the Medical Expenditure Panel Surveys for 2001-2006.

26 Mar 2010

Roche NimbleGen' s microarray technologies help identify genes responsible for CRC

In a recently published study in the journal Genome Research, a team of scientists led by Dr. Shaying Zhao at the University of Georgia have developed a novel cross-species comparative genomics and oncology strategy for cancer driver gene discovery, using microarray technologies from Roche NimbleGen, that differs fundamentally from current approaches which focus on human cancers only.

26 Mar 2010

Educating African Americans on colorectal cancer screening can reduce death rates

Physician experts from the American College of Gastroenterology raised concern that the majority of African Americans are not aware of the recommendation that they should undergo colorectal cancer screening beginning at age 45—five years before current guidelines generally recommend.

26 Mar 2010

Single-incision laparoscopy reduces postoperative complications

Surgeons at the University of California, San Diego School of Medicine report what is believed to be the nation's first single-incision laparoscopy to perform a combined colectomy and kidney-preserving therapy.

26 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

Colorectal News and Research

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Rebirth of the cursed drug Thalidomide

NewYork-Presbyterian Hospital installs high-tech imaging systems for heart and vascular surgeries

2010 DDW conference to highlight breakthrough research on GI health

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Advocates urge Representatives to support Colorectal Cancer Prevention, Early Detection and Treatment Act

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

People with diabetes who undergo cancer surgery have greater risk of death: Study

Genome sequencing of tumors biopsied from women with invasive breast cancer

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

Roche NimbleGen' s microarray technologies help identify genes responsible for CRC

Educating African Americans on colorectal cancer screening can reduce death rates

Single-incision laparoscopy reduces postoperative complications

AVASTIN receives Health Canada approval for patients with GBM

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News